These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10897917)

  • 21. High-dose, frequently administered interferon beta.
    Limmroth V; Putzki N
    J Neurol Sci; 2005 Apr; 231(1-2):95-6; author reply 97-9. PubMed ID: 15792828
    [No Abstract]   [Full Text] [Related]  

  • 22. Changes in circulating dendritic cells and B-cells in patients with multiple sclerosis relapse during corticosteroid therapy.
    Krystyna MS; Jacek T; Sebastian R; Ewa B; Halina BP; Zbigniew S; Jacek R
    J Neuroimmunol; 2009 Feb; 207(1-2):107-10. PubMed ID: 19162336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
    Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
    Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract]   [Full Text] [Related]  

  • 25. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How effective are disease-modifying drugs in delaying progression in relapsing-onset ms?
    Brenner SR; Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2008 Aug; 71(8):615; author reply 615-6. PubMed ID: 18711118
    [No Abstract]   [Full Text] [Related]  

  • 28. Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study.
    Lorefice L; Fenu G; Fois M; Frau J; Coghe G; Marrosu MG; Cocco E
    Mult Scler Relat Disord; 2018 Feb; 20():104-108. PubMed ID: 29360061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
    Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses.
    Morrow SA; Barr J; Rosehart H; Ulch S
    J Affect Disord; 2015 Nov; 187():142-6. PubMed ID: 26334182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
    Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
    J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Adverse effects of treatment with corticosteroids in pharmacological doses].
    Frey H
    Tidsskr Nor Laegeforen; 1976 Nov; 96(31):1662-3. PubMed ID: 982403
    [No Abstract]   [Full Text] [Related]  

  • 34. [Adverse effects of inhaled corticosteroids are dose-dependent].
    Mäkelä M; Haahtela T
    Duodecim; 2003; 119(10):921-2. PubMed ID: 12833782
    [No Abstract]   [Full Text] [Related]  

  • 35. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corticosteroids in atrial fibrillation: Friends or foes?
    Korantzopoulos P
    Arch Intern Med; 2006 Sep; 166(16):1785. PubMed ID: 16983062
    [No Abstract]   [Full Text] [Related]  

  • 37. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
    J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis.
    De Stefano N; Filippi M; Confavreux C; Vermersch P; Simu M; Sindic C; Hupperts R; Bajenaru O; Edan G; Grimaldi L; Marginean I; Medaer R; Orefice G; Pascu I; Pelletier J; Sanders E; Scarpini E; Mancardi GL
    Mult Scler; 2009 Feb; 15(2):238-43. PubMed ID: 18987103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.